Biobank for identifying biomarkers in lung cancer
Official title: Biobank for the Identification of Diagnostic, Prognostic or Therapeutic (Response and Resistance) Biomarkers in Lung Cancer (Early and Advanced Stages of Lung Cancer Cohort of the BIRD (Biomarkers in Respiratory Disease) Biobank)
Run by University Hospital, Toulouse · NCT06054854 · Data updated 2026-11-12
This study is trying to find new ways to diagnose and treat lung cancer by collecting blood samples from patients at different stages of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Status | Recruiting |
| Started | June 13, 2024 |
| Main results expected | October 1, 2033 |
| Study ends | October 1, 2033 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT06054854 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with lung nodules, suspected lung cancer, or confirmed lung cancer at various stages.
✕Probably not a fit
Patients who are pregnant or breastfeeding, or those deprived of liberty, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The BIRD biobank collects clinical and biological data from patients with chronic respiratory diseases, focusing on lung cancer. It divides participants into two cohorts: one for patients with early-stage lung cancer and another for those with advanced-stage lung cancer. The study aims to identify biomarkers through less invasive methods, such as blood samples, to improve diagnosis and treatment options. By analyzing these biomarkers, the research seeks to enhance screening and therapeutic strategies for lung cancer patients.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment options for lung cancer patients.
How similar studies have gone: Other studies have shown promise in identifying biomarkers through non-invasive methods, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with 1 to 3 lung nodules including one \> 1 cm seen on chest CT * OR: patients with suspected lung cancer requiring diagnostic and/or therapeutic bronchial endoscopy * OR: Patient with histologically confirmed lung cancer, whether early stages prior to surgery, locally advanced or metastatic, included before the start of any anti-cancer treatment. * Patient affiliated or beneficiary of a social security scheme * Patients who are able to receive and understand information about the study and their participation and who have freely given their signed inform consent before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and knowledge of the French language). Exclusion Criteria: * Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice * Female patients who are pregnant or breastfeeding
Where it's running
-
Larrey Hospital
Toulouse, France Recruiting
Study contacts
- Principal investigator: Nicolas GUIBERT — University Hospital, Toulouse
- Study coordinator: Nicolas GUIBERT, MD PhD
- Email: guibert.n@chu-toulouse.fr
- Phone: +33567771836
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lung cancer and lung nodules: platelet RNA classifier test
This study tests whether a platelet RNA-based test can help distinguish lung cancer from benign nodules in adults who have a new lung finding or cancer diagnosis.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.